Friend or Foe? The Ambiguous Role of Innate Lymphoid Cells in Cancer Development

Trends in Immunology

Volumn 38, Issue 1, 2017, Pages 29-38

  Mattner, Jochen ^a   Wirtz, Stefan ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR6; EOMESODERMIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 22; INTERLEUKIN 25; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 7; INTERLEUKIN 9; RETINOIC ACID RECEPTOR GAMMA; THYMIC STROMAL LYMPHOPOIETIN; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR; CYTOKINE; TRANSCRIPTOME;

CARCINOGENESIS; CELL PLASTICITY; CYTOKINE RELEASE; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE SUBPOPULATION; LYMPHOID CELL; MARGINAL ZONE LYMPHOMA; NATURAL KILLER CELL; NONHUMAN; PEYER PATCH; REVIEW; TH1 CELL; TH2 CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; CELL GROWTH; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; LYMPHOCYTE; METABOLISM; NEOPLASM; PROCEDURES;

ANIMALS; CARCINOGENESIS; CELL GROWTH PROCESSES; CYTOKINES; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; LYMPHOCYTES; NEOPLASMS; TRANSCRIPTOME;

EID: 85005877137     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2016.10.004     Document Type: Review

References (81)

1. 1 Munn, D.H., Bronte, V., Immune suppressive mechanisms in the tumor microenvironment. Curr. Opin. Immunol. 39 (2016), 1–6.
2. 2 Sonnenberg, G.F., Artis, D., Innate lymphoid cells in the initiation, regulation and resolution of inflammation. Nat. Med. 21 (2015), 698–708.
3. 3 Spits, H., et al. Innate lymphoid cells – a proposal for uniform nomenclature. Nat. Rev. Immunol. 13 (2013), 145–149.
4. 4 von Burg, N., et al. Activated group 3 innate lymphoid cells promote T-cell-mediated immune responses. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), 12835–12840.
5. 5 Krysko, D.V., et al. Immunogenic cell death and DAMPs in cancer therapy. Nature reviews. Cancer 12 (2012), 860–875.
6. 6 Morvan, M.G., Lanier, L.L., NK cells and cancer: you can teach innate cells new tricks. Nat. Rev. Cancer 16 (2016), 7–19.
7. 7 Fuchs, A., et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-gamma-producing cells. Immunity 38 (2013), 769–781.
8. 8 Bernink, J.H., et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat. Immunol. 14 (2013), 221–229.
9. 9 Klose, C.S., et al. Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell 157 (2014), 340–356.
10. 10 Dadi, S., et al. Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T cells. Cell 164 (2016), 365–377.
11. 11 Tugues, S., et al. New insights into IL-12-mediated tumor suppression. Cell Death Differ. 22 (2015), 237–246.
12. 12 Kodama, T., et al. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur. J. Immunol. 29 (1999), 1390–1396.
13. 13 Carnaud, C., et al. Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163 (1999), 4647–4650.
14. 14 Eisenring, M., et al. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat. Immunol. 11 (2010), 1030–1038.
15. 15 Zaidi, M.R., Merlino, G., The two faces of interferon-gamma in cancer. Clin. Cancer Res. 17 (2011), 6118–6124.
16. 16 Bromberg, J.F., et al. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc. Natl. Acad. Sci. U.S.A. 93 (1996), 7673–7678.
17. + T cells requires tumor responsiveness to IFN-gamma. J. Immunol. 166 (2001), 2276–2282.
18. 18 Haabeth, O.A., et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat. Commun., 2, 2011, 240.
19. 19 Hoepner, S., et al. Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumours. PloS ONE, 8, 2013, e63933.
20. + T cells to increase their abundance during virus infection. J. Exp. Med. 201 (2005), 1053–1059.
21. 21 Reiter, Z., Interferon – a major regulator of natural killer cell-mediated cytotoxicity. J. Interferon Res. 13 (1993), 247–257.
22. 22 Martini, M., et al. IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine 28 (2010), 3548–3557.
23. 23 Detjen, K.M., et al. Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut 49 (2001), 251–262.
24. 24 Dighe, A.S., et al. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1 (1994), 447–456.
25. + innate lymphocytes. Immunity 33 (2010), 736–751.
26. 26 Waters, J.P., et al. Tumour necrosis factor and cancer. J. Pathol. 230 (2013), 241–248.
27. 27 Calzascia, T., et al. TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J. Clin. Invest. 117 (2007), 3833–3845.
28. + T cells circumvent immune privilege in the eye and mediate intraocular tumor rejection by a TNF-alpha-dependent mechanism. J. Immunol. 178 (2007), 6115–6122.
29. 29 Kashii, Y., et al. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J. Immunol. 163 (1999), 5358–5366.
30. 30 Prevost-Blondel, A., et al. Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo. J. Immunol. 164 (2000), 3645–3651.
31. 31 Wang, H., et al. Epithelial–mesenchymal transition (EMT) induced by TNF-alpha requires AKT/GSK-3beta-mediated stabilization of snail in colorectal cancer. PloS ONE, 8, 2013, e56664.
32. 32 Balkwill, F., Tumor necrosis factor or tumor promoting factor?. Cytokine Growth Factor Rev. 13 (2002), 135–141.
33. 33 Popivanova, B.K., et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 118 (2008), 560–570.
34. 34 Scott, K.A., et al. An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. Mol. Cancer Ther. 2 (2003), 445–451.
35. + innate lymphoid cells are dysregulated in treatment naive acute myeloid leukemia patients at diagnosis. Haematologica 100 (2015), e257–e260.
36. + group 1 and group 3 innate lymphoid cells in the intestinal lamina propria. Immunity 43 (2015), 146–160.
37. 37 Roediger, B., Weninger, W., Group 2 innate lymphoid cells in the regulation of immune responses. Adv. Immunol. 125 (2015), 111–154.
38. + lymphoid cells. Nature 463 (2010), 540–544.
39. 39 Molofsky, A.B., et al. Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J. Exp. Med. 210 (2013), 535–549.
40. 40 Nussbaum, J.C., et al. Type 2 innate lymphoid cells control eosinophil homeostasis. Nature 502 (2013), 245–248.
41. 41 Bie, Q., et al. Polarization of ILC2s in peripheral blood might contribute to immunosuppressive microenvironment in patients with gastric cancer. J. Immunol. Res., 2014, 2014, 923135.
42. 42 Jovanovic, I.P., et al. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int. J. Cancer 134 (2014), 1669–1682.
43. 43 Mager, L.F., et al. IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. J. Clin. Invest. 125 (2015), 2579–2591.
44. 44 Schwartz, C., et al. Interleukin 33: an innate alarm for adaptive responses beyond Th2 immunity-emerging roles in obesity, intestinal inflammation, and cancer. Eur. J. Immunol. 46 (2016), 1091–1100.
45. 45 Gabitass, R.F., et al. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol. Immunother. 60 (2011), 1419–1430.
46. 46 McHedlidze, T., et al. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity 39 (2013), 357–371.
47. 47 Hams, E., et al. IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), 367–372.
48. 48 Hallett, M.A., et al. Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13. Cancer Res. 72 (2012), 6338–6343.
49. 49 Li, J., et al. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J. Clin. Invest. 124 (2014), 3241–3251.
50. 50 Noval Rivas, M., et al. IL-4 production by group 2 innate lymphoid cells promotes food allergy by blocking regulatory T-cell function. J. Allergy Clin. Immunol. 138 (2016), 801–811.
51. 51 Pelly, V.S., et al. IL-4-producing ILC2s are required for the differentiation of TH2 cells following Heligmosomoides polygyrus infection. Mucosal Immunol. 9 (2016), 1407–1417.
52. 52 Ikutani, M., et al. Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity. J. Immunol. 188 (2012), 703–713.
53. 53 Lotfi, R., et al. Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J. Immunother. 30 (2007), 16–28.
54. 54 Schmitt, E., et al. Th9 cells, new players in adaptive immunity. Trends Immunol. 35 (2014), 61–68.
55. 55 Wilhelm, C., et al. An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat. Immunol. 12 (2011), 1071–1077.
56. 56 Purwar, R., et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat. Med. 18 (2012), 1248–1253.
57. 57 Lu, Y., et al. Th9 cells promote antitumor immune responses in vivo. J. Clin. Invest. 122 (2012), 4160–4171.
58. 58 Kim, I.K., et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells. Nat. Med. 21 (2015), 1010–1017.
59. 59 Lange, K., et al. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. Oncogene 22 (2003), 517–527.
60. 60 Tomas, A., et al. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol. 24 (2014), 26–34.
61. 61 Monticelli, L.A., et al. Innate lymphoid cells: critical regulators of allergic inflammation and tissue repair in the lung. Curr. Opin. Immunol. 24 (2012), 284–289.
62. 62 Busser, B., et al. The multiple roles of amphiregulin in human cancer. Biochim. Biophys. Acta 1816 (2011), 119–131.
63. 63 Zaiss, D.M., et al. Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. Immunity 38 (2013), 275–284.
64. 64 Salimi, M., et al. Group 2 innate lymphoid cells express functional NKp30 receptor inducing type 2 cytokine production. J. Immunol. 196 (2016), 45–54.
65. 65 Cherrier, M., Eberl, G., The development of LTi cells. Curr. Opin. Immunol. 24 (2012), 178–183.
66. + innate lymphoid cells. Nature 494 (2013), 261–265.
67. 67 Buonocore, S., et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464 (2010), 1371–1375.
68. 68 Wang, K., Karin, M., The IL-23 to IL-17 cascade inflammation-related cancers. Clin. Exp. Rheumatol. 33 (2015), S87–S90.
69. 69 Chan, I.H., et al. Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells. Mucosal Immunol. 7 (2014), 842–856.
70. 70 Kirchberger, S., et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J. Exp. Med. 210 (2013), 917–931.
71. 71 Huber, S., et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 491 (2012), 259–263.
72. +ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. Nat. Commun., 6, 2015, 8280.
73. − lymphocytes to treat established melanoma with chemo-immunotherapy. Cancer Immunol. Res. 3 (2015), 296–304.
74. 74 Cella, M., et al. Expansion of human NK-22 cells with IL-7, IL-2, and IL-1beta reveals intrinsic functional plasticity. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 10961–10966.
75. + immature human natural killer cells in secondary lymphoid tissue. Immunity 32 (2010), 803–814.
76. 76 Hughes, T., et al. The transcription factor AHR prevents the differentiation of a stage 3 innate lymphoid cell subset to natural killer cells. Cell Rep. 8 (2014), 150–162.
77. 77 Jiang, R., et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 54 (2011), 900–909.
78. 78 Ohne, Y., et al. IL-1 is a critical regulator of group 2 innate lymphoid cell function and plasticity. Nat. Immunol. 17 (2016), 646–655.
79. 79 Lim, A.I., et al. IL-12 drives functional plasticity of human group 2 innate lymphoid cells. J. Exp. Med. 213 (2016), 569–583.
80. 80 Pikovskaya, O., et al. Eomesodermin is sufficient to direct type 1 innate lymphocyte development into the conventional NK lineage. J. Immunol. 196 (2016), 1449–1454.
81. hi cells are multipotential ‘inflammatory’ type 2 innate lymphoid cells. Nat. Immunol. 16 (2015), 161–169.